Cargando…
Reprogramming Cells to Make Insulin
Type 1 diabetes is a disease characterized by the destruction of insulin-secreting β-cells in the pancreas. Individuals are treated for this disease with lifelong insulin replacement. However, one attractive treatment possibility is to reprogram an individual’s endogenous cells to acquire the abilit...
Autores principales: | McKimpson, Wendy M, Accili, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546342/ https://www.ncbi.nlm.nih.gov/pubmed/31187080 http://dx.doi.org/10.1210/js.2019-00040 |
Ejemplares similares
-
SUN-646 A Novel Population of FOXO1-Expressing Cells in the Stomach Controls Cell Plasticity by Regulating the Cyclin CCNE1
por: McKimpson, Wendy M, et al.
Publicado: (2020) -
FOXO1 Is Present in Stomach Epithelium and Determines Gastric Cell Distribution
por: McKimpson, Wendy M., et al.
Publicado: (2022) -
Inducing and measuring apoptotic cell death in mouse pancreatic β-cells and in isolated islets
por: McKimpson, Wendy M., et al.
Publicado: (2022) -
Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes
por: Kitamoto, Takumi, et al.
Publicado: (2022) -
ARC is essential for maintaining pancreatic islet structure and β-cell viability during type 2 diabetes
por: McKimpson, Wendy M., et al.
Publicado: (2017)